Federal Drug Buying Rules Screen Out the India Generics USCC Favors
Trade Agreements Act origin rules test where a drug's API was made or where it was finished. They do not reach its key starting materials, the inputs the USCC's C2D2 drug plan would verify, and generics finished in India from Indian API are generally ineligible on TAA-covered buys at or above $174,000.
India